Trial Profile
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AN ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY OLDER ADULTS
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Respiratory syncytial virus vaccine Pfizer (Primary) ; Influenza virus vaccine
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 11 May 2022 Results published in the Journal of Infectious Diseases
- 22 Mar 2021 Status changed from completed to discontinued.
- 11 Sep 2020 Status changed from active, no longer recruiting to completed.